Pay in 4 interest-free payments of $5.49 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
It is classified as an unapproved new drug , meaning it cannot be legally marketed, sold, or prescribed as a therapeutic agent
Recent studies show that exposure to GLP1-RA in the first trimester is not associated with a risk of major birth defects when compared with diabetes or obesity
Like cisplatin, it contains two chloride ligands, which are released within the cellular environment and interact with DNA to form intra- and interstrand cross-links.3 These DNA adducts trigger multiple cellular responses, including DNA damage recognition and repair, cell cycle arrest, and activation of apoptotic signaling pathways, ultimately inhibiting cell proliferation.4 Ovarian cancer remains one of the leading causes of mortality among gynecological malignancies, with epithelial ovarian carcinoma accounting for more than 90% of all cases.5 The current standard therapy involves primary cytoreductive surgery followed by platinum-based combination chemotherapy administered as soon as possible after surgery.6 However, a major limitation of these treatments is the dose-dependent toxicity associated with platinum compounds, which can result in significant off-target tissue injury.7 It is well established that Reactive Oxygen Species (ROS) generated during the metabolism of platinum-based agents contribute to this toxicity, particularly in the reproductive system
In contrast, GLP-1, by stimulating the release of insulin, lowers blood glucose
US$ 27.85
US$ 26.13
US$ 22.50
US$ 29.62
US$ 24.63
US$ 29.41
US$ 28.96
US$ 20.02
US$ 27.41
US$ 28.51
US$ 25.45
